



Transforming cancer care through direct alpha therapy

3Q Company update

28 October 2026 · Euronext Oslo: ONCIN



Today's presenters



Oystein Soug
Chief Executive Officer



Ramzi Amri
Chief Financial Officer



Zuzana Jirakova Trnkova
Chief Medical Officer

Disclaimer and important information



This presentation (the “Presentation”) has been prepared by Oncoinvent ASA (the “Company”) for information purposes only and does not constitute, and should not be construed as, an offer to sell, or a solicitation of an offer to buy, any securities of the Company in any jurisdiction. Any securities of the Company may not be offered or sold except pursuant to applicable law and in accordance with applicable registration requirements or exemptions therefrom.

This Presentation is not intended to be, and should not be construed as, legal, tax, investment or other advice. Recipients should consult their own advisers as to the legal, tax, financial, investment and other matters contained herein. By attending a meeting where this Presentation is made and/or by reading these materials, you acknowledge that you are solely responsible for your own assessment of the Company and the information contained in this Presentation.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information contained in this Presentation. Certain information in this Presentation has not been independently verified. The information contained herein is subject to change without notice and the Company does not undertake any obligation to update or revise this Presentation, whether as a result of new information, future events or otherwise, except as required by applicable law.

This Presentation contains forward-looking statements, including, without limitation, statements regarding the Company’s strategy, plans, objectives, milestones, clinical development activities, timelines, trial design and outcomes, regulatory interactions, manufacturing and supply chain readiness, partnering intentions, market opportunity, and expected financial performance and cash runway. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others: the inherent uncertainty in drug development; the ability to initiate, conduct and complete preclinical and clinical studies and obtain expected data within anticipated timelines; patient recruitment and retention; clinical trial site activation and operational execution; safety, tolerability and efficacy outcomes; regulatory review, communications and approvals; changes in applicable laws, regulations and regulatory guidance; manufacturing, quality and supply chain risks (including availability of radionuclides, production capacity, validation and compliance with GMP requirements); reliance on third parties and suppliers; intellectual property protection and freedom to operate; competitive developments; the ability to obtain, maintain and enforce patents and other rights; the ability to enter into and maintain collaborations and partnerships on acceptable terms; pricing, reimbursement and market adoption; and the Company’s ability to raise additional financing when needed. Additional risks and uncertainties are described in the Company’s publicly available disclosures from time to time.

Nothing in this Presentation is intended to be, or should be construed as, medical advice, a diagnosis, or a recommendation regarding any treatment. Any product candidates referenced are investigational and have not been approved for marketing by any regulatory authority, and their safety and efficacy have not been established.

Certain financial and other measures included in this Presentation may not be prepared in accordance with IFRS and may be alternative performance measures (“APMs”). Such measures may not be comparable to similarly titled measures presented by other companies. Definitions and reconciliations, if any, should be read together with the Company’s financial reporting.

The distribution of this Presentation may be restricted by law in certain jurisdictions, and persons into whose possession it comes should inform themselves about, and observe, any such restrictions. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction.

This Presentation speaks as of 28 October 2026. The Company undertakes no obligation to update it except as required by applicable law.

What we will cover today

1 Highlights and operational update

Delivering against our 2026 priorities

CFO

2 New Chief Medical Officer

Introduction

CMO

3 Radspherin and the opportunity

Value proposition, Phase 3 preparation

CEO

Continued strong momentum and operational execution

Radspherin®

71

Patients

Recruited by end 3Q*,
~2/3 of total population

11

Clinical sites

1 new site added during
3Q

1

Publication

Normal tissue dosimetry
results in Journal of
Nuclear Medicine

3

Abstracts presented

ESMO and EANM
Congresses

Corporate

- Successful **Private Placement and Retail Offering** raising gross proceeds of NOK 148.5 million
- Appointed Dr Zuzana Jirakova Trnkova as **CMO**

Delivering against our 2026 priorities



Build momentum in Phase 2 recruitment

Crossed halfway mark and close to 2/3 recruited, Q3 joins Q2 as best quarters so far

DELIVERED



Expand the trial site network

Five sites added in YTD: Italy, UK, Spain (2), Belgium. Eleven now active, more to come

DELIVERED



Clear protocol amendments

All selected amendments approved and showing effect on recruitment

DELIVERED



Disciplined cash burn

NOK 111m per end Q3

DELIVERED



Prepare the ground for Phase 3

Phase 3-enabling private placement
See Outlook section

ON TRACK

Patient recruitment momentum continues to accelerate



Patients recruited, incl. safety run-in, as of 30 September 2026



* Q3 included a 2-week maintenance closure.

The raise takes the company to the April interim readout and funds Phase 3 readiness



NOK 148.5m

Raised in September 2026

Gross proceeds

Efficacy data

April interim readout

2x patients with ≥ 9 months follow-up

Into 2H 2027

Cash runway

Beyond April interim readout

Phase 2

Complete recruitment in 1H 2027

Progress the study beyond a more mature interim readout in April on close to all patients

Regulators and Phase 3

Regulatory alignment with FDA and EMA, prior to Phase 3 IND and CTA submissions

Advance Phase 3 readiness and early start-up activities

Options after the data

With funding beyond readout, we decide on next steps with randomized data in hand

What we will cover today

1 Highlights and operational update
Delivering against our 2026 priorities

CFO

2 New Chief Medical Officer
Introduction

CMO

3 Radspherin and the opportunity
Value proposition, Phase 3 preparation

CEO

Dr Zuzana Jirakova Trnkova as new Chief Medical Officer



Ovarian Cancer – High Unmet Medical Need Remains



Ovarian Cancer – High Unmet Medical Need Remains

AFTER SURGERY

No visible disease

Most women with advanced ovarian cancer leave surgery with no visible disease



YET

Up to 8 in 10

women relapse



THE CAUSE

No visible disease

Peritoneal micrometastases drive relapse in ovarian cancer

What if “no visible disease” could finally mean “no disease”?

Why I joined Oncoinvent



WHY OVARIAN CANCER

- One of the **deadliest** gynecologic cancers
- **Survival** in advanced disease remains **modest**
- **Women's health** as one of the largest remaining **white spaces** in healthcare innovation

WHY RADSPHERIN®

- Many **failed therapeutic approaches** in ovarian cancer
- **Platinum chemotherapy** remains the **backbone** of first-line care
- **Radspherin®** is designed to act exactly **when and where it matters**

WHY ME

20+ years of experience

- **Strategic, medical, operational and regulatory**
- **Phase III** and **alpha-emitter** radiopharmaceuticals
- **Patient-centric** innovation

What we will cover today



1 Highlights and operational update
Delivering against our 2026 priorities

CFO


2 New Chief Medical Officer
Introduction

CMO

3 Radspherin and the opportunity
Value proposition, Phase 3 preparation


CEO

Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy




Cancer in the abdominal cavity is an area with **high unmet need** and few good treatment options

Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy




Micrometastases

Cancer in the abdominal cavity is an area with **high unmet need** and few good treatment options




Oncoinvent develops Radspherin®, a receptor-independent alpha radiopharmaceutical that **eradicates cancer cells in the abdominal cavity after surgery** with a single, targeted dose.

Randomized interim data Phase 2 data planned for late 2026 and March/April 2027



Randomized Phase 2 study in first-line treatment of ovarian cancer



Patient population

- Primary advanced ovarian cancer
- Undergoing neoadjuvant chemotherapy and interval debulking surgery
- Eligible for complete resection
- HRD negative

Primary endpoint

Progression-free survival

11 active study sites



We raised towards phase 3 readiness, supported by an efficacy readout with twice as many evaluable patients

4Q 2026

Interim safety readout

Adverse events mostly appear **early** → safety data matures fast.

First **randomized interim safety data** in **75+ patients**.

FOLLOW-UP

Efficacy matures

Patients enter with **no visible disease**:

- Scanned for recurrence every 3 months
- Few recurrences at 3 and 6 months
- Treatment and control arms expect to separate **after 9 months**

APRIL 2027

Interim efficacy readout

Reading out too early might underplay **real benefit** of Radspherin®.

Faster 2026 recruitment gives **twice as many patients** with 9+ months of follow-up.

A **larger, more mature** dataset de-risks the readout.

Looking ahead: Phase 3 readiness



Trial readiness

Phase 3 trial design and protocol validation in progress



Regulatory readiness

Early engagement with regulators, making full use of the fast-track designation



Manufacturing readiness

Scaling production capacity and progressing CDMO selection and tech transfer readiness



Partnering readiness

Preparing for partnerships and strategic collaborations

Upcoming events: meet the team

